| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Department of Medicine, Division of Hematology/Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007 [N. A. R., J. L. M., W. D., E. N., M. J. H.], and Ligand Pharmaceuticals Inc., San Diego, California 92121 [J. A. T., G. L., G. M. G., E. H. U., R. G., D. J.]
LGD1069 [Targretin; 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl) propenyl] benzoic acid] is a novel synthetic retinoid X receptor-selective retinoid that has been recently identified. The goals of this study were to determine the safety, toxicity, pharmacokinetics (PKs), and metabolic profile of LGD1069 in advanced cancer patients. Sixty patients received oral LGD1069 at doses ranging from 5–1000 mg/m2/day with PK sampling performed on days 1 and 15. No dose-limiting toxicities (DLTs) were observed up to the 500 mg/m2/day dose level. DLT observed at and above 650 mg/m2/day included skin desquamation, hyperbilirubinemia, transaminase elevation, leukopenia, and diarrhea. Asymptomatic, dose-related alterations in lipid and thyroid metabolism were also observed. DLTs frequently observed with retinoic acid receptor-selective retinoids and pan agonists, including headache, mucocutaneous toxicity, and hypercalcemia, were not dose-limiting with LGD1069. Day 1 LGD1069 Cmax and area under the curve values increased dose-proportionately up to 800 mg/m2/day. Repeat-dose (day 15) area under the curve values varied between 25 and 105% of day 1 values. Although no objective tumor responses were observed, tumor progression may have been substantially arrested or delayed in non-small cell lung cancer (5 of 16) and in head and neck cancer (1 of 5), as well as other tumor types. At the higher dose levels, the molar concentration of LGD1069 was up to 10-fold higher than observed with other retinoids, yet toxicity was minimal. LGD1069 is an retinoid X receptor-selective retinoid agonist with a more favorable PK and toxicity profile than previously studied retinoids and merits further investigation as a chemopreventive and anticancer agent. On the basis of this Phase I trial, the recommended Phase II dose is 500 mg/m2/day.
This article has been cited by other articles:
|
|
 |
|
  D. E. Tsai, S. M. Luger, C. Andreadis, D. T. Vogl, A. Kemner, M. Potuzak, A. Goradia, A. W. Loren, A. E. Perl, S. J. Schuster, et al. A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia Clin. Cancer Res., September 1, 2008; 14(17): 5619 - 5625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Blumenschein Jr, F. R. Khuri, J. von Pawel, U. Gatzemeier, W. H. Miller Jr, R. M. Jotte, J. Le Treut, S.-L. Sun, J. K. Zhang, Z. E. Dziewanowska, et al. Phase III Trial Comparing Carboplatin, Paclitaxel, and Bexarotene With Carboplatin and Paclitaxel in Chemotherapy-Naive Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: SPIRIT II J. Clin. Oncol., April 10, 2008; 26(11): 1879 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ramlau, P. Zatloukal, J. Jassem, P. Schwarzenberger, S. V. Orlov, M. Gottfried, J. R. Pereira, G. Temperley, R. Negro-Vilar, S. Rahal, et al. Randomized Phase III Trial Comparing Bexarotene (L1069-49)/Cisplatin/Vinorelbine With Cisplatin/Vinorelbine in Chemotherapy-Naive Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: SPIRIT I J. Clin. Oncol., April 10, 2008; 26(11): 1886 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Govindan, J. Crowley, L. Schwartzberg, P. Kennedy, C. Williams, B. Ekstrand, A. Sandler, D. Jaunakais, V. Bolejack, and R. Ghalie Phase II Trial of Bexarotene Capsules in Patients With Advanced Non-Small-Cell Lung Cancer After Failure of Two or More Previous Therapies J. Clin. Oncol., October 20, 2006; 24(30): 4848 - 4854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Desvergne, L. Michalik, and W. Wahli Transcriptional Regulation of Metabolism Physiol Rev, April 1, 2006; 86(2): 465 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Dragnev, W. J. Petty, S. Shah, A. Biddle, N. B. Desai, V. Memoli, J. R. Rigas, and E. Dmitrovsky Bexarotene and Erlotinib for Aerodigestive Tract Cancer J. Clin. Oncol., December 1, 2005; 23(34): 8757 - 8764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Edelman, R. Smith, P. Hausner, L. A. Doyle, K. Kalra, J. Kendall, M. Bedor, and S. Bisaccia Phase II Trial of the Novel Retinoid, Bexarotene, and Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., August 20, 2005; 23(24): 5774 - 5778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-Y. Lee, Y. S. Chang, J.-Y. Han, D. D. Liu, J. J. Lee, R. Lotan, M. R. Spitz, and W. K. Hong Effects of 9-cis-Retinoic Acid on the Insulin-Like Growth Factor Axis in Former Smokers J. Clin. Oncol., July 1, 2005; 23(19): 4439 - 4449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Budgin, S. K. Richardson, S. B. Newton, M. Wysocka, M. H. Zaki, B. Benoit, and A. H. Rook Biological Effects of Bexarotene in Cutaneous T-Cell Lymphoma Arch Dermatol, March 1, 2005; 141(3): 315 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Lubet, K. Christov, N. P. Nunez, S. D. Hursting, V. E. Steele, M.M. Juliana, I. Eto, and C. J. Grubbs Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis Carcinogenesis, February 1, 2005; 26(2): 441 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Rigas and K. H. Dragnev Emerging Role of Rexinoids in Non-Small Cell Lung Cancer: Focus on Bexarotene Oncologist, January 1, 2005; 10(1): 22 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Konopleva, E. Elstner, T. J. McQueen, T. Tsao, A. Sudarikov, W. Hu, W. D. Schober, R.-Y. Wang, D. Chism, S. M. Kornblau, et al. Peroxisome proliferator-activated receptor {gamma} and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias Mol. Cancer Ther., October 1, 2004; 3(10): 1249 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Ogilvie, R. Saladin, T. R. Nagy, M. S. Urcan, R. A. Heyman, and M. D. Leibowitz Activation of the Retinoid X Receptor Suppresses Appetite in the Rat Endocrinology, February 1, 2004; 145(2): 565 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Kurie, R. Lotan, J. J. Lee, J. S. Lee, R. C. Morice, D. D. Liu, X.-C. Xu, F. R. Khuri, J. Y. Ro, W. N. Hittelman, et al. Treatment of Former Smokers With 9-cis-Retinoic Acid Reverses Loss of Retinoic Acid Receptor-{beta} Expression in the Bronchial Epithelium: Results From a Randomized Placebo-Controlled Trial J Natl Cancer Inst, February 5, 2003; 95(3): 206 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wu, Y. Zhang, X.-C. Xu, J. Hill, J. Celestino, H.-T. Kim, S. K. Mohsin, S. G. Hilsenbeck, W. W. Lamph, R. Bissonette, et al. The Retinoid X Receptor-Selective Retinoid, LGD1069, Prevents the Development of Estrogen Receptor-Negative Mammary Tumors in Transgenic Mice Cancer Res., November 15, 2002; 62(22): 6376 - 6380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Rizvi, J. L. Marshall, E. Ness, M. J. Hawkins, C. Kessler, H. Jacobs, W. D. Brenckman Jr, J. S. Lee, W. Petros, W. K. Hong, et al. Initial Clinical Trial of Oral TAC-101, a Novel Retinoic Acid Receptor-Alpha Selective Retinoid, in Patients With Advanced Cancer J. Clin. Oncol., August 15, 2002; 20(16): 3522 - 3532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Dy and A. A. Adjei Novel Targets for Lung Cancer Therapy: Part I J. Clin. Oncol., June 15, 2002; 20(12): 2881 - 2894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wu, H.-T. Kim, J. L. Rodriquez, S. G. Hilsenbeck, S. K. Mohsin, X.-C. Xu, W. W. Lamph, J. G. Kuhn, J. E. Green, and P. H. Brown Suppression of Mammary Tumorigenesis in Transgenic Mice by the RXR-selective Retinoid, LGD1069 Cancer Epidemiol. Biomarkers Prev., May 1, 2002; 11(5): 467 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhang, P. Hazarika, X. Ni, D. A. Weidner, and M. Duvic Induction of Apoptosis by Bexarotene in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic Action Clin. Cancer Res., May 1, 2002; 8(5): 1234 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Smith and B. Anderson Where to Next with Retinoids for Cancer Therapy? Clin. Cancer Res., October 1, 2001; 7(10): 2955 - 2957. [Full Text] [PDF]
|
|
|
|
|
|
J. I. Song, M. N. Lango, J. D. Hwang, S. D. Drenning, Q. Zeng, W. W. Lamph, and J. R. Grandis Abrogation of Transforming Growth Factor-{alpha}/Epidermal Growth Factor Receptor Autocrine Signaling by an RXR-selective Retinoid (LGD1069, Targretin) in Head and Neck Cancer Cell Lines Cancer Res., August 1, 2001; 61(15): 5919 - 5925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Khuri, J. R. Rigas, R. A. Figlin, R. J. Gralla, D. M. Shin, R. Munden, N. Fox, M. R. Huyghe, Y. Kean, S. D. Reich, et al. Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., May 15, 2001; 19(10): 2626 - 2637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Duvic, K. Hymes, P. Heald, D. Breneman, A. G. Martin, P. Myskowski, C. Crowley, and R. C. Yocum Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results J. Clin. Oncol., May 1, 2001; 19(9): 2456 - 2471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Duvic, A. G. Martin, Y. Kim, E. Olsen, G. S. Wood, C. A. Crowley, R. C. Yocum, and for the Worldwide Bexarotene Study Group Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma Arch Dermatol, May 1, 2001; 137(5): 581 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. A. Davies, S. A. Berry, G. L. Shipley, R. H. Eckel, N. Hennuyer, D. L. Crombie, K. M. Ogilvie, J. Peinado-Onsurbe, C. Fievet, M. D. Leibowitz, et al. Metabolic Effects of Rexinoids: Tissue-Specific Regulation of Lipoprotein Lipase Activity Mol. Pharmacol., February 1, 2001; 59(2): 170 - 176. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
